Kissei Pharmaceutical Co., Ltd.
4547.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.51 | 0.20 | -1.09 | 0.06 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 29.60 | 43.37 | 27.04 | 29.08 |
| Quality | ||||
| ROIC | -3.58% | 0.73% | 0.52% | 0.87% |
| Gross Margin | 49.10% | 49.93% | 48.31% | 50.51% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 8.59% | 8.21% | 9.38% | 7.60% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -7.25 | -8.44 | -4.59 | -3.11 |
| Interest Coverage | -1,278.00 | 351.33 | 256.00 | 409.50 |
| Efficiency | ||||
| Inventory Turnover | 0.46 | 0.44 | 0.47 | 0.43 |
| Cash Conversion Cycle | 246.18 | 268.81 | 274.33 | 294.87 |